ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2464

Thymic Size Longitudinal Changes on Chest High-resolution Computed Tomography After Autologous Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2273

Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 1940

Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 1935

Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2338

TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1960

To Biopsy or Not to Biopsy: Imaging Features of Chronic Nonbacterial Osteomyelitis of the Clavicle

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1769

Top Peripheral Blood Transcriptomic Gene Modules Reveal Functional Annotation and Correlation with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups

Pediatric Rheumatology – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 2128

Trabecular Bone Score Curve from a Qatari Population, Data from Qatar Biobank

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2185

TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, a Feasibility Study

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1836

Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 2215

Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2016

Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2346

Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis

SpA Including PsA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2093

Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial

Osteoarthritis – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 2491

Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data

Vasculitis – ANCA-Associated Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].